Italia markets open in 26 minutes

Genocea Biosciences, Inc. (0A51.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,00010,0000 (0,00%)
Alla chiusura: 03:15PM GMT
Schermo intero
Chiusura precedente0,0001
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume0
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,99
Rapporto PE (ttm)N/D
EPS (ttm)-0,5330
Prossima data utili08 mar 2023 - 13 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Genocea Announces Wind Down of Operations and Delisting From NASDAQ

    CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist

  • GlobeNewswire

    Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

    CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of th

  • GlobeNewswire

    Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

    GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clinical findings PLANETTM manufacturing process is highly reliable and continues to improve; patients next to be dosed to receive GEN-011 with substantially boosted yields, neoantigen specificity and potency Investor webcast at 4: